Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma

Journal of Clinical Oncology

Volumn 24, Issue 24, 2006, Pages 4011-4019

  Yan, Tristan D ^a   Black, Deborah ^a   Savady, Renaldo ^a   Sugarbaker, Paul H ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; IRINOTECAN; ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; HUMAN; MORBIDITY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL RATE; SYSTEMATIC REVIEW; ADJUVANT CHEMOTHERAPY; CARCINOMA; COLORECTAL TUMOR; CONSENSUS DEVELOPMENT; DRUG INSTILLATION; HYPERTHERMIC THERAPY; METASTASIS; PATHOLOGY; PATIENT SELECTION; PERITONEAL CAVITY; PERITONEUM TUMOR; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CONSENSUS DEVELOPMENT CONFERENCES; HUMANS; HYPERTHERMIA, INDUCED; INSTILLATION, DRUG; PATIENT SELECTION; PERITONEAL CAVITY; PERITONEAL NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33748460503     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.07.1142     Document Type: Review

References (61)

1. Chu DZ, Lang NP, Thompson C, et al: Peritoneal carcinomatosis in nongynecologic malignancy: A prospective study of prognostic factors. Cancer 63:364-367, 1989
2. Jayne DG, Fook S, Loi C, et al: Peritoneal carcinomatosis from colorectal cancer. Br J Surg 89:1545-1550, 2002
3. Sadeghi B, Arvieux C, Glehen O, et al: Peritoneal carcinomatosis from non-gynecologic malignancies: Results of the EVOCAPE 1 multicentric prospective study. Cancer 88:58-63, 2000
4. Hurwitz HI, Fehrenbacher L, Hainsworth JD, et al: Bevacizumab in combination with fluorouracil and leucovorin: An active regimen for first-line metastatic colorectal cancer. J Clin Oncol 23:3502-3508, 2005
5. Kabbinavar FF, Schulz J, McCleod M, et al: Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: Results of a randomized phase II trial. J Clin Oncol 23:3697-3705, 2005
6. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004
7. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicenter randomized trial. Lancet 355:1041-1047, 2000
8. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 18:136-147, 2000
9. Rothenberg ML, Oza AM, Bigelow RH, et al: Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial. J Clin Oncol 21:2059-2069, 2003
10. Colucci G, Gebbin V, Paoletti G, et al: Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23:4866-4875, 2005
11. Glehen O, Osinsky D, Beaujard AC, et al: Natural history of peritoneal carcinomatosis from nongynecologic malignancies. Surg Oncol Clin N Am 12:729-739, 2003
12. Willst CG, Tepper JE, Cohen AM, et al: Failure patterns following curative resection of colonic carcinoma. Surgery 200:685-690, 1984
13. Schott A, Vogel I, Krueger U, et al: Isolated tumor cells are frequently detected in peritoneal cavity of gastric and colonic cancer patients and serve as a new prognostic marker. Ann Surg 227: 372-379, 1998
14. Sugarbaker PH, Graves T, DeBruijn EA, et al: Rationale for early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gastrointestinal cancer. Cancer Res 50:5790-5794, 1990
15. Katz M, Barone R: The rationale of perioperative intraperitoneal chemotherapy in the treatment of peritoneal surface malignancies. Surg Oncol Clin N Am 12:673-688, 2003
16. Sugarbaker PH: New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome. Lancet Oncol 7:69-76, 2006
17. Feldman AL, Libutti SK, Pingpank JF, et al: Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21:4560-4567, 2003
18. Look M, Chang D, Sugarbaker PH: Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 14:35-41, 2004
19. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:77-79, 2006
20. Sugarbaker PH, Jablonski KA: Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 221:124-132, 1995
21. Sugarbaker PH, Schellinx MET, Chang D, et al: Peritoneal carcinomatosis from adenocarcinoma of the colon. World J Surg 20:585-592, 1996
22. Pestieau SR, Sugarbaker PH: Treatment of primary colon cancer with peritoneal carcinomatosis: Comparison of concomitant vs. delayed management. Dis Colon Rectum 43:1341-1348, 2000
23. Carmignani CP, Ortega-Perez G, Sugarbaker PH: The management of synchronous peritoneal carcinomatosis and hematogenous metastasis from colorectal cancer. Eur J Surg Oncol 30:391-398, 2004
24. Gomes da Silva RG, Cabanas J, Sugarbaker PH: Limited survival in the treatment of carcinomatosis from rectal cancer. Dis Colon Rectum 48:2258-2263, 2005
25. Gomes da Silva RG, Sugarbaker PH: Analysis of 10 prognostic factors in 70 patients having complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. Am J Coll Surg in press
26. Beaujard AC, Glehen O, Caillot JL, et al: Intraperitoneal chemohyperthermia with mitomycin C for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 88:2512-2519, 2000
27. Glehen O, Mithieux F, Osinsky D, et al: Surgery combined with peritoneotomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: A phase II study. J Clin Oncol 21:799-806, 2003
28. Glehen O, Cotte E, Schreiber V, et al: Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 91: 747-754, 2004
29. Glehen O, Kwiatkowski F, Sugarbaker PH, et al: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study. J Clin Oncol 22: 3284-3292, 2004
30. Elias D, Blot F, El Otmany A, et al: Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 92:71-76, 2001
31. Elias DM, Ouellet JF: Intraperitoneal chemohyperthermia: Rationale, techniques, indications, and results. Surg Oncol Clin N Am 10:915-933, 2001
32. Elias D, Pocard M, Sideris L, et al: Preliminary results of intraperitoneal chemohyperthermia with oxaliplatin in peritoneal carcinomatosis of colorectal origin. Br J Surg 91:455-456, 2004
33. Elias D, Delperro JR, Sideris L, et al: Treatment of peritoneal carcinomatosis from colorectal cancer: Impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 11:518-521, 2004
34. Elias D, Raynard B, Farkhondeh F, et al: Peritoneal carcinomatosis of colorectal origin: Long-term results of intraperitoneal chemohyperthermia with oxaliplatin following complete cytoreductive surgery. Gastroenterol Clin Biol (in press)
35. Witkamp AJ, de Bree E, Kaag MM, et al: Extensive cytoreductive surgery followed by intraoperative hyperthermic intraperitoneal chemotherapy with mitomycin C in patients with peritoneal carcinomatosis of colorectal origin. Eur J Cancer 37:979-984, 2001
36. Verwaal VJ, van Tinteren H, van Ruth S, et al: Predicting the survival of patients with peritoneal carcinomatosis of colorectal origin treated by aggressive cytoreduction and hyperthermic intraperitoneal chemotherapy. Br J Surg 91:739-746, 2004
37. Verwaal VJ, van Tinteren H, Ruth SV, et al: Toxicity of cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy. J Surg Oncol 85:61-67, 2004
38. Verwaal VJ, Boot H, Aleman BM, et al: Recurrences after peritoneal carcinomatosis of colorectal origin treated by cytoreduction and hyperthermic intraperitoneal chemotherapy: Location, treatment, and outcome. Ann Surg Oncol 11:375-379, 2004
39. Verwaal VJ, Zoetmulder FA: Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 30:280-285, 2004
40. Verwaal VJ, van Ruth S, Witkamp A, et al: Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 12:65-71, 2005
41. Loggie BW, Fleming RA, McQuellon RP, et al: Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of gastrointestinal origin. Am Surg 66:561-568, 2000
42. Shen P, Levine EA, Hall J, et al: Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg 138:26-33, 2003
43. Shen P, Hawksworth J, Lovato J, et al: Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol 11:178-186, 2004
44. Cavaliere F, Di Filippo F, Botti C, et al: Peritoneotomy and hyperthermic antiblastic perfusion in the treatment of peritoneal carcinomatosis. Eur J Surg Oncol 26:486-491, 2000
45. Cavaliere F, Perri P, Di Filippo F, et al: Treatment of peritoneal carcinomatosis with intent to cure. J Surg Oncol 74:41-44, 2000
46. Schneebaum S, Arnold MW, Staubus A, et al: Intraperitoneal hyperthermic perfusion with mitomycin C for colorectal cancer with peritoneal metastases. Ann Surg Oncol 3:44-50, 1996
47. Pilati P, Mocellin S, Rossi CR, et al: Cytoreductive surgery combined with hyperthermic intraperitoneal intraoperative chemotherapy for peritoneal carcinomatosis arising from colon adenocarcinoma. Ann Surg Oncol 10:508-513, 2003
48. Kecmanovic DM, Pavlov MJ, Ceranic MS, et al: Treatment of peritoneal carcinomatosis from colorectal cancer by cytoreductive surgery and hyperthermic perioperative intraperitoneal chemotherapy. Eur J Surg Oncol 31:147-152, 2005
49. Yan TD, Links M, Glenn D, et al: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal peritoneal carcinomatosis - A prospective study of 30 patients. Eur J Surg Oncol (in press)
50. Verwaal VJ, van Ruth S, de Bree E, et al: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal origin. J Clin Oncol 21:3737-3743, 2003
51. NHS Centre for Reviews and Dissemination: Undertaking Systemic Reviews of Research on Effectiveness: CRD's Guidance for Those Carrying Out or Commissioning Reviews - CRD Report 4 (ed 2). York, United Kingdom, NHS Centre for Reviews and Dissemination, 2001
52. Glehen O, Gilly FN: Quantitative prognostic indicators of peritoneal surface malignancy: Carcinomatosis, sarcomatosis, and peritoneal mesothelioma. Surg Oncol Clin N Am 12:649-671, 2003
53. Mahteme H, Hansson J, Berglund A, et al: Improved survival in patients with peritoneal metastases from colorectal cancer: A preliminary study. Br J Cancer 90:403-407, 2004
54. Glimelius B, Jakobsen A, Graf W, et al: Bolus injection (2-4 min) versus short-term (10-20 min) infusion of 5-fluorouracil in patients with advanced colorectal cancer: A prospective randomized trial. Eur J Cancer 34:674-678, 1998
55. McQuellon RP, Loggie BW, Fleming RA, et al: Quality of life after intraperitoneal hyperthermic chemotherapy (IPHC) for peritoneal carcinomatosis. Eur J Surg Oncol 27:65-73, 2001
56. McQuellon RP, Loggie BW, Lehman AB, et al: Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol 10:155-162, 2003
57. Torres IL, Litterst CL, Guarino AM: Transport of model compounds across the peritoneal membrane in the rat. Pharmacology 17:330-340, 1978
58. Jacquet P, Averbach A, Stuart OA, et al: Hyperthermic intraperitoneal doxorubicin: Pharmacokinetics, metabolism and tissue distribution in a rate model. Cancer Chemother Pharmacol 41:147-154, 1998
59. Los G, Smals OAG, van Vugt MJH, et al: A rationale for carboplatin treatment and abdominal hyperthermia in cancers restricted to the peritoneal cavity. Cancer Res 52:1252-1258, 1992
60. van Ruth S, Verwaal VJ, Zoetmulder FAN: Pharmacokinetics of intraperitoneal mitomycin C. Surg Oncol N Am 12:771-780, 2003
61. Yan TD, Haveric N, Carmignani CP, et al: Abdominal computed tomography scans in the selection of patients with malignant peritoneal mesothelioma for comprehensive treatment with cytoreductive surgery and perioperative intraperitoneal chemotherapy. Cancer 103:839-849, 2005